Literature DB >> 16952638

Changing patterns of pelvic lymphadenectomy for prostate cancer: results from CaPSURE.

Jun Kawakami1, Maxwell V Meng, Natalia Sadetsky, David M Latini, Janeen Duchane, Peter R Carroll.   

Abstract

PURPOSE: Widespread screening for prostate cancer in the United States has resulted in earlier tumor identification at lower stages. The fewer number of men with lymph node metastases at initial presentation has altered patterns of pelvic lymphadenectomy before definitive treatment. We characterized patterns of pelvic lymphadenectomy in conjunction with radical prostatectomy in a community based cohort.
MATERIALS AND METHODS: In the CaPSURE database we identified men undergoing radical prostatectomy. Patients were stratified into 3 clinical risk groups based on serum prostate specific antigen, T stage and pathological grade. We examined temporal trends of pelvic lymphadenectomy and predictors of pelvic lymphadenectomy.
RESULTS: From 1992 to 2004 the proportion of men undergoing pelvic lymphadenectomy in conjunction with radical prostatectomy decreased from 94% to 80%. Overall positive lymph nodes were identified in 0.87%, 2.0% and 7.1% of men in the low, intermediate and high risk groups, respectively. While men with high risk disease continued to undergo pelvic lymphadenectomy at a high rate (greater than 90%), the fraction of men at low and intermediate risk undergoing pelvic lymphadenectomy steadily decreased. Prostate specific antigen, Gleason sum, clinical stage and income were factors associated with pelvic lymphadenectomy. A mean of 5.7 lymph nodes (median 5.0) were removed.
CONCLUSIONS: The performance of pelvic lymphadenectomy has decreased in patients at low and intermediate risk, and remained stable in patients at high risk. Further investigation of the role of extended pelvic lymphadenectomy and the potential therapeutic benefits of pelvic lymphadenectomy would better define the contemporary role of pelvic lymphadenectomy and identify appropriate candidates.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16952638     DOI: 10.1016/j.juro.2006.06.001

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  19 in total

1.  Should all men having a radical prostatectomy have a pelvic lymph node dissection? No.

Authors:  Firas Abdollah; Maxine Sun; Rodolphe Thuret; Pierre I Karakiewicz
Journal:  Can Urol Assoc J       Date:  2010-12       Impact factor: 1.862

2.  Why all prostate cancer surgery should include an adequate lymph node dissection.

Authors:  D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2010-12       Impact factor: 1.862

3.  [Seminal vesicle sparing radical perineal prostatectomy].

Authors:  S Schäfers; P de Geeter; H Löhmer; P Albers
Journal:  Urologe A       Date:  2009-04       Impact factor: 0.639

Review 4.  Reducing morbidity of pelvic and retroperitoneal lymphadenectomy.

Authors:  Mark W Ball; Michael A Gorin; Mohamad E Allaf
Journal:  Curr Urol Rep       Date:  2013-10       Impact factor: 3.092

5.  Pelvic lymph node dissection for patients with elevated risk of lymph node invasion during radical prostatectomy: comparison of open, laparoscopic and robot-assisted procedures.

Authors:  Jonathan L Silberstein; Andrew J Vickers; Nicholas E Power; Raul O Parra; Jonathan A Coleman; Rodrigo Pinochet; Karim A Touijer; Peter T Scardino; James A Eastham; Vincent P Laudone
Journal:  J Endourol       Date:  2011-11-08       Impact factor: 2.942

6.  Complications of pelvic lymphadenectomy: do the risks outweigh the benefits?

Authors:  Stacy Loeb; Alan W Partin; Edward M Schaeffer
Journal:  Rev Urol       Date:  2010

7.  Comparison of nomograms predicting lymph node invasion in patients undergoing radical prostatectomy for prostate cancer.

Authors:  G J Nason; E M O'Connor; D MacMahon; B Moss; S W Considine; A Cahill; C O'Rourke; F M O'Brien
Journal:  Ir J Med Sci       Date:  2017-05-06       Impact factor: 1.568

8.  Role of androgen deprivation therapy for node-positive prostate cancer.

Authors:  Yu-Ning Wong; Stephen Freedland; Brian Egleston; Gary Hudes; J Sanford Schwartz; Katrina Armstrong
Journal:  J Clin Oncol       Date:  2008-12-01       Impact factor: 44.544

Review 9.  A review of high-risk prostate cancer and the role of neo-adjuvant and adjuvant therapies.

Authors:  Joshua R Gonzalez; Melissa A Laudano; Tara R McCann; James M McKiernan; Mitchell C Benson
Journal:  World J Urol       Date:  2008-09-02       Impact factor: 4.226

10.  Detection of Lymph Node Metastases with SERRS Nanoparticles.

Authors:  Massimiliano Spaliviero; Stefan Harmsen; Ruimin Huang; Matthew A Wall; Chrysafis Andreou; James A Eastham; Karim A Touijer; Peter T Scardino; Moritz F Kircher
Journal:  Mol Imaging Biol       Date:  2016-10       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.